Sleep Health Enhancement in Midlife Adults
Launched by UNIVERSITY OF KANSAS MEDICAL CENTER · Mar 7, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Sleep Health Enhancement in Midlife Adults," is exploring how improving sleep can help midlife adults (ages 45-64) possibly delay or prevent Alzheimer's disease (AD). The researchers want to create a program that focuses on better sleep habits and see if it is effective, acceptable, and feasible for people in this age group. They believe that enhancing sleep health could play an important role in reducing the risk of developing Alzheimer's.
To participate in this trial, you need to be between 45 and 64 years old and have a self-reported sleep quality score of 7 or lower. You should also have a good understanding of your mental functions and not show signs of severe depression or anxiety. Some conditions, like untreated sleep disorders or certain mental health issues, will exclude you from participating. If eligible, you can expect to engage in a sleep health improvement program designed specifically for midlife adults, which aims to help you sleep better and potentially improve your overall health. The study is currently recruiting participants, and your involvement could contribute to important findings about sleep and brain health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 45-64 years old
- • ≤ 7 on the RU-SATED self-report questionnaire
- • MMSE ≥25 and AD8 \<3
- Exclusion Criteria:
- • Known untreated sleep disorder (such as sleep apnea or restless leg syndrome)
- • \>3 on the STOP BANG indicating increased risk of sleep apnea
- • Increased risk of restless legs syndrome on RLS-Diagnosis Index
- • Evidence of circadian rhythm sleep-wake disorder
- • Evidence of parasomnia
- • Regular use (\>2x/week) of prescription or over-the-counter medications to improve sleep
- • Score of ≥15 on the Patient Health Questionnaire (PHQ-9) indicating severe depression or endorsement of any suicidal ideation (answer 1, 2 or 3 on #9 of the PHQ-9)
- • Score of ≥10 on the Generalized Anxiety Disorder (GAD-7) indicating moderate to severe anxiety
- • Self-report of current or history (up to 2 years) of drug or alcohol abuse based on the DSM-5-TR criteria
- • History of nervous system disorder such as stroke or Parkinson's disease
- • Severe mental illness such as schizophrenia or bipolar disorder
- • Current or history (within 5 years) of shift work including hours of midnight-4am
- • Is currently receiving a behavioral sleep health intervention
About University Of Kansas Medical Center
The University of Kansas Medical Center (KUMC) is a leading academic medical institution dedicated to advancing healthcare through innovative research, education, and clinical practice. As a prominent clinical trial sponsor, KUMC leverages its extensive expertise in diverse medical fields to conduct rigorous clinical research aimed at improving patient outcomes and developing new treatment modalities. With a commitment to ethical standards and patient safety, KUMC collaborates with multidisciplinary teams to facilitate groundbreaking studies that address significant health challenges, ultimately contributing to the advancement of medical knowledge and the enhancement of community health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported